Haemonetics VASCADE MVP XL Shows Superior Safety Profile in Large-Bore Venous Closure Study

Key Takeaways

• VASCADE MVP XL demonstrates superior safety and efficacy compared to standard VASCADE MVP in large-bore venous closure procedures
• FDA approved expanded labeling for the device in March 2026, broadening its clinical applications
• Study results support wider adoption of the XL system for complex vascular procedures requiring larger access sites

---

BOSTON - Haemonetics Corporation (NYSE: HAE) announced publication of a comparative study evaluating its VASCADE MVP XL vascular closure system against the standard VASCADE MVP device for large-bore venous access closure procedures.

The study, published following FDA approval of expanded labeling in March 2026, provides clinical evidence supporting the enhanced capabilities of the XL system in managing larger venous access sites. The research compared safety and efficacy outcomes between the two closure systems in patients undergoing procedures requiring substantial venous access.

Enhanced Performance in Complex Procedures

The VASCADE MVP XL system demonstrated improved performance metrics in large-bore venous closure applications, addressing a critical need in interventional procedures that require larger access sites. The device utilizes advanced closure technology designed to provide secure hemostasis while minimizing complications.

“This study reinforces our commitment to developing innovative vascular closure solutions that improve patient outcomes,” said a Haemonetics spokesperson. The company’s focus on medical technology innovation continues to drive advancement in vascular access management.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Clinical Adoption

The expanded FDA labeling positions Haemonetics to capture a larger share of the vascular closure device market, particularly in complex interventional procedures. Healthcare providers now have clinical data supporting the use of VASCADE MVP XL in scenarios previously limited to alternative closure methods.

The study results are expected to influence clinical practice guidelines and support broader adoption of the XL system in hospitals performing high-volume interventional procedures. This development strengthens Haemonetics’ competitive position in the growing vascular closure market.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Future Implications

With regulatory approval and supporting clinical evidence, Haemonetics is positioned to expand market penetration of the VASCADE MVP XL system. The company continues investing in research and development to advance vascular closure technology and improve patient care outcomes.

---

Frequently Asked Questions

What makes VASCADE MVP XL different from the standard version?

The XL system is specifically designed for large-bore venous access closure procedures, offering enhanced capabilities for managing larger access sites with improved safety and efficacy profiles.

When did FDA approve the expanded labeling?

The FDA approved expanded labeling for VASCADE MVP XL in March 2026, broadening its approved clinical applications for large-bore venous procedures.

How does this impact patient treatment options?

Patients undergoing procedures requiring large-bore venous access now have access to a closure system with demonstrated superior safety and efficacy, potentially reducing complications and improving recovery outcomes.

Related coverage

• Breast Cancer Statistics Worldwide: What the Data Shows
• Obesity rates in America by year: what the data shows
• Moderna's mRNA-1083 Phase 3 shows stronger flu and COVID immune responses